Research Topics
| Jeffrey A ZonderSummaryAffiliation: Wayne State University Country: USA Publications
|
Detail Information
Publications
Practical aspects of the treatment of chronic myelogenous leukemia with imatinib mesylateJeffrey A Zonder
Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Harper Hospital, 4 Brush South, 3990 John R, Detroit, MI 48201, USA
Curr Hematol Rep 2:57-64. 2003..The feasibility of combining imatinib with other agents also needs to be examined, as does the utility of molecular monitoring of response. Finally, developing methods to overcome resistance to imatinib is a looming challenge...
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myelomaJeffrey A Zonder
Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R St, Detroit, MI 48201, USA
Blood 120:552-9. 2012..5%) had stable disease. In summary, elotuzumab was generally well tolerated in this population, justifying further exploration of this agent in combination regimens...- Chronic lymphocytic leukemia presenting in association with aplastic anemiaJeffrey A Zonder
Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
Am J Hematol 71:323-7. 2002..Possible humoral and cellular autoimmune mechanisms are examined as possible causes of marrow aplasia in this setting... - The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatmentJeffrey A Zonder
Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
Clin Cancer Res 9:2092-7. 2003..Some patients with chronic-phase or accelerated-phase CML either relapse after an initial response or are refractory to imatinib, prompting us to evaluate the efficacy of dose increase in such patients... - Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylateJeffrey A Zonder
Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R, Detroit, MI 48201, USA
Curr Hematol Malig Rep 1:141-51. 2006..Finally, recent data on new tyrosine kinase inhibitors capable of overcoming primary or acquired resistance to imatinib are reviewed... 
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)Jeffrey A Zonder
Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
Blood 116:5838-41. 2010..001; thromboembolic events despite aspirin prophylaxis: 23.5% [initial LEN-DEX or crossover] vs 5%; P < .001). This trial was registered at www.clinicaltrials.gov as #NCT00064038...- Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation studySuzanne Lentzsch
Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, PA, USA
Blood 119:4608-13. 2012..This first phase 1/2 trial testing bendamustine, lenalidomide, and dexamethasone as treatment of relapsed refractory MM was feasible and highly active. This study is registered at www.clinicaltrials.gov as #NCT01042704... - Clinical development of novel proteasome inhibitors for cancer treatmentHuanjie Yang
The Prevention Program, Barbara Ann Karmanos Cancer Institute, and the Department of Pathology, School of Medicine, Wayne State University, 540 1 HWCRC, 4100 John R Road, Detroit, Michigan 48201, USA
Expert Opin Investig Drugs 18:957-71. 2009..Emerging evidence demonstrates that targeting the tumor proteasome is a promising strategy for cancer therapy...